Abstracts tagged "safety and biomarkers"

Abstract Number: 2175 • ACR/ARP Annual Meeting 2019

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of the Anti-ADAMTS-5 Nanobody®, M6495, in Healthy Male Subjects: A Phase I, Placebo-Controlled, First-in-Human Study

Hans Guehring¹, Torben Balchen ², Kosalaram Goteti ³, Jesper Sonne ⁴, Christoph Ladel ¹, Victor Ona ¹, Flavie Moreau ⁵, Anne Bay-Jensen ⁶ and Asger Reinstrup Bihlet ⁶, ¹Merck KGaA, Darmstadt, Germany, ²DanTrials ApS c/o Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ³EMD Serono Research and Development Institute, Inc., Billerica, MA, ⁴Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁵EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁶Nordic Bioscience, Herlev, Denmark